Oncopeptides Balance Sheet Health
Financial Health criteria checks 4/6
Oncopeptides has a total shareholder equity of SEK228.4M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK316.9M and SEK88.5M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 251.90m |
| Equity | SEK 228.42m |
| Total liabilities | SEK 88.46m |
| Total assets | SEK 316.88m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ONCOS's short term assets (SEK296.9M) exceed its short term liabilities (SEK84.0M).
Long Term Liabilities: ONCOS's short term assets (SEK296.9M) exceed its long term liabilities (SEK4.4M).
Debt to Equity History and Analysis
Debt Level: ONCOS is debt free.
Reducing Debt: ONCOS has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONCOS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ONCOS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22.9% each year